What amount sold does TRANSGENOMIC INC report in Form D filings?

The latest linked filings report $67M sold across 15 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was TRANSGENOMIC INC's most recent SEC filing?

TRANSGENOMIC INC's most recent Form D filing was on 2017-11-20.

How many investors does TRANSGENOMIC INC have?

The most recent Form D filing lists 4 investor(s).

TRANSGENOMIC INC

CIK: 0001043961·Biotechnology·New Haven, CT·Corporation

Reported Sold

$67,019,732

Total Filings

Identified Offerings

Last Filed

Nov 20, 2017

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Nov 20, 2017Form D — New notice

Reported sold: $810,840 · Target: $810,840

Rule 506(b)·4 investors

Jul 17, 2017Form D — New notice

Reported sold: $8,269,459 · Target: $8,269,459

Rule 506(b)·3 investors

Jul 14, 2017Form D — New notice

Reported sold: $800,000 · Target: $800,000

Rule 506(b)·6 investors

Jul 14, 2017Form D — New notice

Reported sold: $0 · Target: Indefinite

Rule 506(b)·45 investors

Jul 14, 2017Form D — New notice

Reported sold: $399,997 · Target: $399,997

Rule 506(b)·3 investors

Apr 26, 2017Form D — New notice

Reported sold: $1,150,000 · Target: $1,250,000

Rule 506(b)·5 investors

Jan 20, 2016Form D — New notice

Reported sold: $2,199,676 · Target: $2,199,676

Rule 506(b)·5 investors

Jul 17, 2015Form D — New notice

Reported sold: $3,039,760 · Target: $3,039,760

Rule 506(b)·2 investors

Jan 26, 2015Form D/A — Amendment

Reported sold: $1,675,000 · Target: $1,675,000

Rule 506(b)·8 investors

Changed: Reported amount sold, Offering target, Reported investors, Sales commissions

Jan 15, 2015Form D — New notice

Reported sold: $750,000 · Target: $750,000

Rule 506(b)·1 investor

Oct 27, 2014Form D — New notice

Reported sold: $2,375,000 · Target: $2,375,000

Rule 506(b)·9 investors

Mar 14, 2014Form D — New notice

Reported sold: $7,000,000 · Target: $7,000,000

Rule 506(b)·3 investors

Feb 6, 2013Form D — New notice

Reported sold: $8,300,000 · Target: $8,300,000

Rule 506·32 investors

Feb 13, 2012Form D — New notice

Reported sold: $22,000,000 · Target: $22,000,000

Rule 506·56 investors

Jan 13, 2012Form D — New notice

Reported sold: $3,000,000 · Target: $3,000,000

Rule 506·3 investors

Jan 10, 2011Form D — New notice

Reported sold: $6,000,000 · Target: $6,000,000

Rule 506·3 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

$2,488,223

Amendment Rate

Latest reported sold across 15 identified offerings

$67,019,732

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Robert M. Patzig

Related Person

Appears on 8 filings

Doit L. Koppler II

Related Person

Appears on 8 filings

Paul Kinnon

Related Person

Appears on 7 filings

Mark Rimer

Related Person

Appears on 5 filings

Ilan Danieli

Related Person

Appears on 5 filings

Carl Iberger

Related Person

Appears on 5 filings

Michael A. Luther

Related Person

Appears on 4 filings

Leon F. Richards

Related Person

Appears on 4 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Nov 20, 2017	New	$810,840	$810,840	4
Jul 17, 2017	New	$8,269,459	$8,269,459	3
Jul 14, 2017	New	$800,000	$800,000	6
Jul 14, 2017	New	Indefinite	$0	45
Jul 14, 2017	New	$399,997	$399,997	3
Apr 26, 2017	New	$1,250,000	$1,150,000	5
Jan 20, 2016	New	$2,199,676	$2,199,676	5
Jul 17, 2015	New	$3,039,760	$3,039,760	2
Jan 26, 2015	Amendment	$1,675,000	$1,675,000	8
Jan 15, 2015	New	$750,000	$750,000	1
Oct 27, 2014	New	$2,375,000	$2,375,000	9
Mar 14, 2014	New	$7,000,000	$7,000,000	3
Feb 6, 2013	New	$8,300,000	$8,300,000	32
Feb 13, 2012	New	$22,000,000	$22,000,000	56
Jan 13, 2012	New	$3,000,000	$3,000,000	3
Jan 10, 2011	New	$6,000,000	$6,000,000	3

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Allyx Therapeutics, Inc.

Biotechnology

Offering target: $29,999,999

Filed Oct 21, 2026